Gender‐related issues in the pharmacology of new anti‐obesity drugs
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Summary: Four new medicines—liraglutide, lorcaserin, bupropion/naltrexone, and phentermine/topiramate—have been recently added to the pharmacological arsenal for obesity treatment and could represent important tools to manage this epidemic disease. To achieve satisfactory anti‐obesity goals, the use of these new medicines should be optimized and tailored to specific patient subpopulations also by applying dose adjustments if needed. In the present review, we posit that gender could be among the factors influencing the activity of the new obesity drugs both because of pharmacokinetic and pharmacodynamic factors. Although evidence from premarketing clinical studies suggested that no dose adjustment by gender is necessary for any of these new medicines, these studies were not specifically designed to identify gender‐related differences. This observation, together with the strong theoretical background supporting the hypothesis of a gender‐dimorphic response, strongly call upon an urgent need of new real‐life data on gender‐related difference in the pharmacology of these new obesity drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Anatomy and regulation of the central melanocortin system
Cone, R. D. (2005) · Nature Neuroscience · doi:10.1038/nn1455 · Cited by 1,583
Astrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M. F., & Lean, M. E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61375-1 · Cited by 1,163 · cited 1×
“Because a substantial weight loss was noticed in patients with diabetes treated with this drug, the hypothesis that liraglutide could be used for weight reduction in patients with obesity was raised and formally demonstrated in randomized clinical trials finally leading to its approval as an anti‐obesity drug.(67,68)…”
ResultBecker, J. B., & Hu, M. (2008) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2007.07.003 · Cited by 1,003 · cited 1×
“Sex steroids modulate the expression of monoamino‐oxidases, noradrenaline and dopamine transporters, and vesicular monoamine transporters,(40-42) and this could account for the gender differences observed in amphetamines and cocaine psychostimulant effect.(111,112) It is well established, indeed, that the addiction po…”
BackgroundThe arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
Secher, A., Jelsing, J., Baquero, A. F., Hecksher-Sørensen, J., Cowley, M. A., Dalbøge, L. S., Hansen, G., Grove, K. L., Pyke, C., Raun, K., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci75276 · Cited by 961
The sexual dimorphism of obesity
Palmer, B. F., & Clegg, D. J. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2014.11.029 · Cited by 919 · cited 2×
“com/j more in men than women, possibly because visceral fat worsens insulin resistance, lipid profile, and fluid metabolism much more than subcutaneous fat.(1) Nevertheless, very few studies addressed the question of whether gender also contributes to the response to anti‐obesity treatment.”
BackgroundGlucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms
I˙meryüz, N., Yeğen, B. Ç., Bozkurt, A., Coşkun, T., Villanueva-Peñacarrillo, M. L., & Ulusoy, N. B. (1997) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.1997.273.4.g920 · Cited by 432 · cited 1×
“An additionalmechanismof liraglutide anorexigenic effect is the ability of this drug to activate gastric vagal afferents, thereby slowing gastric emptying and promoting an early sense of satiety via central mechanisms.(16) Although it is well established that gastric emptying is slower in women than in men,(17) no stu…”
BackgroundDickson, S. L., Shirazi, R. H., Hansson, C., Bergquist, F., Nissbrandt, H., & Skibicka, K. P. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.6326-11.2012 · Cited by 414 · cited 1×
“in the ventral tegmental area (VTA) and in the nucleus accumbens (NAc), key nodes of the central reward circuitry.(70) Functional magnetic resonance imaging (fMRI) studies showed that other brain regions such as insula, amygdala, and orbitofrontal cortex are also involved in food reward mechanisms and that their activ…”
BackgroundGraaf, C. D., Donnelly, D., Wootten, D., Lau, J., Sexton, P. M., Miller, L. J., Ahn, J.-M., Liao, J., Fletcher, M. M., Yang, D., et al. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011395 · Cited by 403
Sex and estrogens alter the action of glucagon-like peptide-1 on reward
Richard, J. E., Anderberg, R. H., López-Ferreras, L., Olandersson, K., & Skibicka, K. P. (2016) · Biology of Sex Differences · doi:10.1186/s13293-016-0059-9 · Cited by 102
Antagonistic modulation of NPY/AgRP and POMC neurons in the arcuate nucleus by noradrenalin
Paeger, L., Karakasilioti, I., Altmüller, J., Frommolt, P., Brüning, J., & Kloppenburg, P. (2017) · eLife · doi:10.7554/elife.25770 · Cited by 57 · cited 1×
“Indeed, dopaminergic and noradrenergic terminals located in the arcuate and in the paraventricular nuclei control hunger and satiety.(81,82) Most of the effects of hypothalamic monoaminergic systems on feeding are supposed to converge on the regulation of POMC neurons that represent key mediators of anorexigenic respo…”
BackgroundThe anorectic effect of fenfluramine is increased by estradiol treatment in ovariectomized rats
RIVERA, H., & ECKEL, L. (2005) · Physiology & Behavior · doi:10.1016/j.physbeh.2005.08.004 · Cited by 47
Acute HPA axis response to naltrexone differs in female vs. male smokers
Roche, D. J. O., Childs, E., Epstein, A. M., & King, A. C. (2010) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2009.09.016 · Cited by 33
Cited by
Sex/gender differences in obesity prevalence, comorbidities, and treatment
Cooper, A. J., Gupta, S. R., Moustafa, A. F., & Chao, A. M. (2021) · Current Obesity Reports · doi:10.1007/s13679-021-00453-x · Cited by 483
Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand?
Tak, Y. J., & Lee, S. Y. (2021) · Current Obesity Reports · doi:10.1007/s13679-020-00422-w · Cited by 343
Muscogiuri, G., Verde, L., Vetrani, C., Barrea, L., Savastano, S., & Colao, A. (2023) · Journal of Endocrinological Investigation · doi:10.1007/s40618-023-02196-z · Cited by 164
“Some evidence from preclinical investigations suggests that the central anorexigenic effect of the naltrexone/bupropion combination could be modulated by sex steroids [49].”
BackgroundInfluentialSelf-citationAnti-Inflammatory Effects of GLP-1 Receptor Activation in the Brain in Neurodegenerative Diseases
Diz-Chaves, Y., Mastoor, Z., Spuch, C., González-Matías, L. C., & Mallo, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179583 · Cited by 148
“With regards to data from preregistration, clinical trials show that liraglutide exposure is about 32% higher in women than in men after adjusting for body weight [102,103]; and different pharmacokinetics have been described with a higher rate of drug degradation in men when compared with women [102,103].”
BackgroundLautenbach, A., Wernecke, M., Huber, T. B., Stoll, F., Wagner, J., Meyhöfer, S. M., Meyhöfer, S., & Aberle, J. (2022) · Obesity Surgery · doi:10.1007/s11695-022-06211-9 · Cited by 92
Metadata
- Authors
- Cataldi, M., Muscogiuri, G., Savastano, S., Barrea, L., Guida, B., Taglialatela, M., & Colao, A.
- Venue
- Obesity Reviews
- Publisher
- Wiley
- Published
- 2018-12-27
- Volume
- 20
- Issue
- 3
- Pages
- 375-384
- ISSN
- 1467-7881 (ISSN-L)
- 1467-789X
- OpenAlex
- W2908423447
- Cited by
- 36
- References
- 13
- FWCI
- 2.03
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.